

## **Igenica Appoints Thi-Sau Migone, Ph.D., as Chief Scientific Officer**

BURLINGAME, CA – April 9, 2013 – Igenica, Inc., an innovative biopharmaceutical company focused on the discovery and development of first-in-class antibody-based therapeutics for the treatment of cancer, today announced the appointment of Thi-Sau Migone, Ph.D., to the role of Chief Scientific Officer.

Dr. Migone brings wide-ranging experience in the discovery and development of novel therapeutic antibodies. Dr. Migone joins Igenica from Human Genome Sciences, where she held a variety of executive positions and most recently served as Vice President of Research. In that role, she led scientific programs ranging from early discovery through Biologics License Applications, including belimumab and raxibacumab, two antibody programs that reached regulatory approval under her scientific leadership. Prior to Human Genome Sciences, Dr. Migone held research positions at DNAX Research Institute, the National Heart, Lung and Blood Institute and National Institute of Allergy and Infectious Diseases. Dr. Migone received a doctoral degree in Biological Sciences from the University of Pavia, Italy.

“Dr. Migone has a track record of leading and advancing biotherapeutics programs from discovery to successful product approval,” said Mary Haak-Frendscho, Ph.D., Chief Executive Officer of Igenica. “She brings an exceptional skillset and talent to Igenica at a time of great promise for Igenica’s platform and first-in-class antibody-based therapeutic programs.”

“Igenica has developed an integrated suite of differentiated technologies and capabilities supporting the discovery of novel cancer targets, antibodies and antibody-drug conjugates. The Company is building a pipeline of next-generation cancer therapeutics that have significant potential to improve outcomes for cancer patients,” said Dr. Migone. “I am delighted to have this opportunity to contribute to Igenica’s success.”

### **About Igenica, Inc.**

Igenica, Inc. is a biopharmaceutical company pioneering breakthrough antibody-based cancer medicines. The company has integrated innovative technology platforms to address the major challenges to developing effective treatments for multiple oncology indications, with sTAG, a forward-looking proteomics approach to discovering novel tumor antigens, iTAb, a functional in vivo antibody screening approach, and next generation antibody-drug

conjugate technology. Igenica's technology platforms drive innovative drug discovery and promise to identify novel and more effective cancer therapeutics.

Igenica's Board of Directors includes David Goeddel, Ph.D., The Column Group; John Diekman, Ph.D., 5AM Ventures; Mark A. Goldsmith, M.D., Ph.D., Third Rock Ventures; Carl Gordon, Ph.D., CFA, Orbimed Advisors; Mary Haak-Frendscho, Ph.D., Igenica, Inc.; Robert Schreiber, Ph.D., Igenica Founder and Alumni Endowed Professor of Pathology and Immunology, Professor of Molecular Microbiology and Tumor Immunology Program Leader for the Siteman Comprehensive Cancer Center at Washington University School of Medicine.

**Contact:**

John K. Celebi, MBA  
Chief Business Officer  
Igenica, Inc.  
(650) 231-4320